View Item 

Show simple item record

Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials
dc.contributor.authorGoldstein, J. L.en_US
dc.contributor.authorChan, Francis K. L.en_US
dc.contributor.authorLanas, Angelen_US
dc.contributor.authorWilcox, C. M.en_US
dc.contributor.authorPeura, D.en_US
dc.contributor.authorSands, G. H.en_US
dc.contributor.authorBerger, M. F.en_US
dc.contributor.authorNguyen, H.en_US
dc.contributor.authorScheiman, James M.en_US
dc.date.accessioned2011-11-10T15:31:12Z
dc.date.available2012-12-03T21:17:29Zen_US
dc.date.issued2011-10en_US
dc.identifier.citationGoldstein, J. L.; Chan, F. K. L.; Lanas, A.; Wilcox, C. M.; Peura, D.; Sands, G. H.; Berger, M. F.; Nguyen, H.; Scheiman, J. M. (2011). "Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials." Alimentary Pharmacology & Therapeutics 34(7). <http://hdl.handle.net/2027.42/86811>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86811
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleHaemoglobin decreases in NSAID users over time: an analysis of two large outcome trialsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.en_US
dc.contributor.affiliationotherDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, USA.en_US
dc.contributor.affiliationotherDepartment of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong.en_US
dc.contributor.affiliationotherUniversity of Zaragoza, Aragon Health Research Institute (IIS Aragón) CIBERehd, Spain.en_US
dc.contributor.affiliationotherDivision of Gastroenterology/Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA.en_US
dc.contributor.affiliationotherDivision of Gastroenterology and Hepatology, University of Virginia Health Sciences Center, Charlottesville, VA, USA.en_US
dc.contributor.affiliationotherPfizer Inc, New York, NY, USA.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86811/1/j.1365-2036.2011.04790.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2011.04790.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceScheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32: 667 – 77.en_US
dc.identifier.citedreferenceAllison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749 – 54.en_US
dc.identifier.citedreferenceLanas A, Sopena F. Nonsteroidal anti‐inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am 2009; 38: 333 – 52.en_US
dc.identifier.citedreferenceBombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520 – 8.en_US
dc.identifier.citedreferenceCannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long‐term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771 – 81.en_US
dc.identifier.citedreferenceSchnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665 – 74.en_US
dc.identifier.citedreferenceSilverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti‐inflammatory drugs. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 1995; 123: 241 – 9.en_US
dc.identifier.citedreferenceSilverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti‐inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247 – 55.en_US
dc.identifier.citedreferenceSingh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS‐I Study. Am J Med 2006; 119: 255 – 66.en_US
dc.identifier.citedreferenceBjarnason I, O’Morain C, Levi AJ, Peters TJ. Absorption of 51chromium‐labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318 – 22.en_US
dc.identifier.citedreferenceChan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104 – 10.en_US
dc.identifier.citedreferenceGoldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133 – 41.en_US
dc.identifier.citedreferenceGraham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small‐intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55 – 9.en_US
dc.identifier.citedreferenceLaine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288 – 92.en_US
dc.identifier.citedreferenceThiefin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72: 286 – 94.en_US
dc.identifier.citedreferenceChan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173 – 9.en_US
dc.identifier.citedreferenceChan FK, Cryer B, Goldstein JL, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010; 37: 167 – 74.en_US
dc.identifier.citedreferenceFDA. Advisory Committee Briefing Document. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf. Accessed January 4, 2010.en_US
dc.identifier.citedreferenceChaves PH, Xue QL, Guralnik JM, Ferrucci L, Volpato S, Fried LP. What constitutes normal hemoglobin concentration in community‐dwelling disabled older women? J Am Geriatr Soc 2004; 52: 1811 – 6.en_US
dc.identifier.citedreferenceEisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 2006; 20: 213 – 26.en_US
dc.identifier.citedreferencePenninx BW, Pluijm SM, Lips P, et al. Late‐life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005; 53: 2106 – 11.en_US
dc.identifier.citedreferencePenninx BW, Pahor M, Woodman RC, Guralnik JM. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci 2006; 61: 474 – 9.en_US
dc.identifier.citedreferenceFDA. Gastrointestinal Drug Advisory Committee Meeting. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM231990.pdf. Accessed January 4, 2010.en_US
dc.identifier.citedreferenceLanas A. A review of the gastrointestinal safety data‐‐a gastroenterologist’s perspective. Rheumatology (Oxford) 2010; 49 ( Suppl 2 ): ii3 – 10.en_US
dc.identifier.citedreferencePenninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004; 52: 719 – 24.en_US
dc.identifier.citedreferenceGoldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007; 25: 1211 – 22.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2011.04790.x.pdf
Size:
395.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.